GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
Jemperli was the first drug in the class to be approved for front-line use in endometrial cancer last year, based on progression-free survival data from RUBY, but with a restricted label that ...
Jemperli – the seventh approved drug in the PD-1/PD-L1 inhibitor class – was acquired by GSK as part of its $5.1 billion takeover of Tesaro along with PARP inhibitor Zejula (niraparib ...
The overhanging Zantac litigation case has dented investor confidence, even though GSK settled a major US class action last year ... The success of new launches such as Jemperli in endometrial cancer ...
The overhanging Zantac litigation case has dented investor confidence, even though GSK settled a major US class action last ... success of new launches such as Jemperli in endometrial cancer ...
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...
The latest 247Sports 2025 transfer rankings created a ton of movement within the top 300 or so ranked players, which gives us an opportunity to re-evaluate the classes. Each team approaches the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results